Navigation Links
Ready-To-Use Products Spur the European Tissue Sealants and Topical Hemostats Markets, Says Frost & Sullivan
Date:1/27/2009

LONDON, Jan. 27 /PRNewswire/ -- Cannibalisation, high market complexity and significant barriers to entry are all influencing the European tissue sealants and topical hemostats markets. However, the increase in complex surgeries and anticipated technology innovations are continuing to drive growth. Ready-to-use products will ensure market expansion.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.medicaldevices.frost.com), European Tissue Sealants and Topical Hemostats Market, finds that the markets earned revenues of $338.5 million in 2007 and estimates this to reach $645.6 million in 2014.

"The European tissue sealants and topical hemostats markets are driven primarily by the need for quicker and more effective surgeries," notes the Frost & Sullivan analyst. "Additionally, combination products and ready-to-use patches will invigorate market revenues."

The ability to reduce post-operative times will also boost the sale of ready-to-use patches. In addition, fibrin sealants should expand beyond typical wound care applications to be used as drug delivery mechanisms and in adhesion prevention, thus increasing the scope of the market in the future.

However, the dominance of a few large participants will deter the entry of new competitors with innovative products. Furthermore, the lack of proper product positioning will trigger cannibalisation in the market.

"There are high entry barriers in the European tissue sealants and topical hemostats markets," Frost & Sullivan explains. "Apart from domination by a handful of large companies, regulatory issues and the long gestation period also affect the entry of prospective participants. The complex nature of the market itself poses a challenge for its growth."

Industry participants should concentrate on gaining clarity in product positioning and achieving product differentiation in the minds of end users. Diversification into untapped markets, manufacturing ready-to-use products and entering into strategic alliances will be some of the keys to survival in these markets.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the European tissue sealants and topical hemostats market, then send an e-mail to Katja Feick, Corporate Communications, at katja.feick@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by e-mail.

European Tissue Sealants and Topical Hemostats Market is part of the Medical Devices Growth Partnership Service programme, which also includes research in the following markets: European Urinary Incontinence Devices Market, European Ophthalmic Surgical Devices Market, European Insulin Delivery Devices Market. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit http://www.frost.com.

European Tissue Sealants and Topical Hemostats Market

M2F8

    Contact:
    Katja Feick
    Corporate Communications - Europe
    P: +49 (0) 69 77 0 33 43
    E: katja.feick@frost.com
   http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Physician Skin Care Specialist Says Proposed New Rules for Sunscreen Products Will Better Protect the Public
3. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
4. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
5. Why Are Most Health & Wellness Products Doomed to Failure?
6. GladRags Introduces the Moon Cup - An Environmentally-Sound and Safe Alternative to Disposable Feminine Hygiene Products!
7. Consumer Specialty Products Association Highly Critical of NRDC Study on Home Air Fresheners
8. Thomson Healthcare Endorsed as Preferred Vendor of Information Products and Services for Virginia Hospitals
9. New RAPS White Paper Details Career Development of Healthcare Products Regulatory Professionals
10. UniCare Introduces Consumer-Driven Health Products to Give Consumers a Bigger Role in Health Care Decisions
11. Caxton-Iseman Capital Acquires Conney Safety Products, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... NY (PRWEB) , ... May 27, 2016 , ... With ... intervention to walk, the demand for a sustainable product to aid in the rehabilitation ... and aid in the recovery of individuals with hemiplegia due to stroke. , Ekso ...
(Date:5/27/2016)... ... May 27, 2016 , ... In response ... many who are unaware of the plight of aphasia. In collaboration with the ... “Stroke Awareness” campaign. , The link between stroke and aphasia is relatively unknown, ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees in ... come courtesy of leaders in the nursing and health care industry. It also provides ... associations—namely Abilene Christian University. , As the nursing industry is coming out of ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Despite last ... meeting, expect Janet Yellen and company to wait until March 2017 for an interest ... University’s J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) ...
(Date:5/26/2016)... ... 2016 , ... Cabot Corporation, Pfizer, and 3M are responsible ... documents and SEC filings. A jury has returned a verdict of $32.8 ... Case No. BC588866, Los Angeles County, California. The jury awarded $22.8 million in ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... LifeScienceIndustryResearch.com adds "Ulcerative Colitis ... with comprehensive information on the therapeutic development for ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Ulcerative Colitis ...
(Date:5/27/2016)... -- Hutchison China MediTech (Chi-Med) (HCM) ... highly lucrative global oncology and immunology markets. HCM ... or best-in-class tyrosine kinase inhibitor (TKI) drugs, some ... HCM,s profitable Chinese healthcare business continues to benefit ... of the mid-to-late-stage pipeline during 2016-17 (including US ...
(Date:5/26/2016)... India , May 26, 2016 ... drugs market growth is the emergence of new treatments. ... astaxanthin therapies for osteoarthritis treatment. The therapy is expected ... Moreover, Arthritis Research UK is conducting studies to develop ... arcOGEN study, where the genes involved in osteoarthritis are ...
Breaking Medicine Technology: